• Pandemic Response Box Compounds Against MDR Bacterial and Fu

  2026-05-15

  This study systematically evaluates compounds from the MMV Pandemic Response Box for activity against multidrug-resistant A. baumannii, P. aeruginosa, and major fungal clinical isolates. The findings identify several candidates with promising in vitro efficacy, highlighting the utility of high-throughput screening in addressing urgent antimicrobial resistance challenges.

• Maraviroc (UK-427857): Targeting CCR5 in RA and Beyond

  2026-05-15

  Explore how Maraviroc (UK-427857) advances research on CCR5, not only in HIV-1 entry inhibition but also in rheumatoid arthritis and inflammation. This article uniquely analyzes extracellular vesicle biology and recent breakthroughs for translational immunology.

• Mitoxantrone HCl: DNA Topoisomerase II Inhibitor in Cancer R

  2026-05-14

  Mitoxantrone HCl empowers researchers with robust, reproducible workflows for apoptosis induction, resistance modeling, and nuclear receptor modulation. Its dual-action mechanism as a DNA topoisomerase II inhibitor and ERα disruptor unlocks advanced use-cases in leukemia, multiple sclerosis, and stem cell research.

• Gepotidacin vs Nitrofurantoin: Phase 3 Evidence in UTI Thera

  2026-05-14

  The EAGLE-2 and EAGLE-3 trials demonstrate that oral gepotidacin, a first-in-class triazaacenaphthylene antibiotic, is non-inferior—and in one trial, superior—to nitrofurantoin for treating uncomplicated urinary tract infections in females. These findings highlight gepotidacin’s potential against drug-resistant uropathogens and underscore evolving strategies for combating antimicrobial resistance.

• Applied Use-Cases of 5-(N,N-dimethyl)-Amiloride Hydrochlorid

  2026-05-13

  5-(N,N-dimethyl)-Amiloride hydrochloride empowers precise control of Na+/H+ exchanger activity, enabling robust investigation of intracellular pH regulation and endothelial injury pathways. This guide translates recent biomarker-driven findings and workflow insights into actionable, reproducible protocols for cardiovascular, cell viability, and endothelial permeability studies.

• Ethacridine Lactate Monohydrate: Antiseptic Agent for Microb

  2026-05-13

  Ethacridine lactate monohydrate enables precise, high-purity microbial inhibition in advanced biochemical and epigenetic assays. Its integration streamlines contamination control while supporting reproducibility in complex differentiation workflows, as exemplified by recent super-enhancer research.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod

  2026-05-12

  This study provides a comprehensive analysis of how the pathological state of metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids in mice. Its findings offer key mechanistic insights for optimizing therapeutic dosing strategies in MASH and highlight the impact of disease-driven changes in drug metabolism and transporter expression.

• Amyloid β-Peptide (1-42): Workflows & Optimization in AD Res

  2026-05-12

  Unlock robust Alzheimer's disease models using Amyloid β-Peptide (1-42) (Aβ42) with precise, evidence-backed workflows. Discover advanced assay enhancements, troubleshooting strategies, and insights from key reference studies to maximize neurotoxicity and ion channel modulation research.

• Proteoform-Specific Drug Targeting in Native Cell Signaling

  2026-05-11

  This article examines a recent Nature Chemistry study that pioneers native top-down mass spectrometry for mapping drug-protein interactions at the proteoform level within unmodified lipid bilayers. The findings reveal differential off-target binding of cGMP-specific phosphodiesterase type 5 inhibitors, such as sildenafil, to distinct retinal proteoforms, offering new insights for personalized drug design.

• Lipoamino Bundle LNPs Enable Spleen-Targeted mRNA Delivery

  2026-05-11

  This study introduces lipoamino bundle lipid nanoparticles (LNPs) as a chemically evolved platform for efficient mRNA transfection of dendritic cells and macrophages, with pronounced spleen-selectivity in vivo. The work provides mechanistic insights into LNP design for immune-targeted mRNA delivery, significant for vaccine and immunotherapy research.

• Precision in Coagulation: Advanced Utility of Thrombin B Cha

  2026-05-10

  Explore the pivotal role of thrombin, a trypsin-like serine protease, in orchestrating fibrinogen to fibrin conversion and vascular modeling. This article uniquely analyzes assay implications and practical considerations for using Coagulation Factor II (Thrombin) B Chain Fragment [Homo sapiens], providing researchers with a distinctive, evidence-driven perspective.

• ddhCTP (3ʹ-deoxy-3′,4ʹ-didehydro-CTP): Mechanism, Evidence,

  2026-05-09

  ddhCTP is a biologically derived RNA virus replication inhibitor produced via viperin’s radical SAM enzymatic activity. This nucleotide analog interrupts viral RNA synthesis by targeting viral polymerases, with demonstrated efficacy against flaviviruses in cell and animal models. Its application enables precise benchmarking in antiviral drug development and mechanistic studies.

• Technical Guide: Angiotensin I/II (1-5) in Hypertension Rese

  2026-05-09

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide for modeling blood pressure regulation and aldosterone release within the renin-angiotensin system. It is suitable for cardiovascular and renal workflows but should not be used in unrelated peptide signaling studies or outside its validated solubility and mechanistic context.

• Hypoxia and Immunometabolism: Mechanisms in Tumor Microenvir

  2026-05-08

  This review dissects the mechanisms by which hypoxia and immune metabolism co-shape the tumor microenvironment, emphasizing metabolic reprogramming and immune evasion. The findings have practical implications for research targeting redox state and oxidative stress in cancer.

• Zosuquidar (LY335979) 3HCl for Reliable MDR Reversal in Canc

  2026-05-07

  This article presents actionable, scenario-driven guidance for overcoming multidrug resistance (MDR) in cell-based assays using Zosuquidar (LY335979) 3HCl (SKU A3956). Drawing on validated data and practical experience, it addresses common laboratory pitfalls, protocol optimization, and product selection, ensuring robust and reproducible results for biomedical researchers.

466 records 19/32 page Previous Next First page 上5页 1617181920 下5页 Last page